Skin and eyelid inflammation affects thousands of Australians and New Zealanders every year.
Over 85 per cent of skin and eyelid inflammation patients also suffer from inflammatory ocular conditions such as meibomian gland dysfunction, blepharitis and eyelid telangiectasia.1
Lumenis invites you to think outside the eye and offer your patients a solution to their skin related problems with M22.
M22 combines intense pulsed light and unique optimal pulse technology and is intended to treat 20 different skin indications, including rosacea and other skin inflammatory conditions.
Contact: Lumenis (AUS) 1800 586 364
- Viso E, Millán AC, and Rodríguez-Ares MT, Rosacea-associated meibomian gland dysfunction – an epidemiological perspective, Eur Ophthalmol Rev, 2014; 8(1):13-16.